HDL biology
A review names CETP among four enzyme mutations that reshape HDL particle size and regulate HDL cholesterol and apoA-I levels (Curr Opin Lipidol 1996)
Original title: Unravelling high density lipoprotein-apolipoprotein metabolism in human mutants and animal models
This review synthesizes human and animal studies on HDL-apolipoprotein metabolism. Kinetic studies establish that variation in plasma HDL cholesterol and apoA-I is primarily driven by apoA-I catabolic rate, while apoA-II levels are primarily driven by production rate. Genetic factors substantially influence HDL cholesterol and apoA-I and apoA-II levels: mutations in genes encoding lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein (CETP), hepatic lipase, and lipoprotein lipase regulate HDL cholesterol and apoA-I by modifying HDL lipid content and particle size. Recent transgenic and knockout animal studies confirm the key role of these HDL lipid-modifying proteins and have expanded understanding of how lipid modification determines plasma HDL cholesterol and apoA-I concentrations, as well as the potential functional roles of apoA-II.
Original abstract
Apolipoprotein A-I plays an essential structural and functional role in HDL metabolism and apolipoprotein A-II has important effects on HDL metabolism and function. Kinetic studies in humans have established that variation in plasma HDL-cholesterol and apolipoprotein A-I concentrations is primarily determined by variation in the rate of apolipoprotein A-I catabolism. In contrast, plasma apolipoprotein A-II levels are primarily determined by the rate of apolipoprotein A-II production. Genetic factors play an important role in modulating the plasma levels of HDL-cholesterol and apolipoproteins A-I and A-II. Studies in humans have established that mutations in genes encoding enzymes that esterify cholesterol (lecithin : cholesterol acyltransferase), transfer cholesterol (cholesteryl ester transfer protein) and hydrolyze lipids (hepatic lipase, lipoprotein lipase) regulate HDL-cholesterol and apolipoprotein A-I levels by modifying the lipid content (and therefore the size) of HDL particles. Recent studies in transgenic and knockout animals have confirmed the key role of HDL lipid-modifying proteins in HDL, apolipoprotein A-I and apolipoprotein A-II metabolism and have expanded our understanding of the role of lipid modification in determining plasma concentrations of HDL-cholesterol and apolipoprotein A-I, as well as the potential functional roles of apolipoprotein A-II.
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 19 August 2026. Methods.